Summary of Oculis Holding AG (OCS) Conference Call Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on innovations in ophthalmology and neuro-ophthalmology [3][4] - The company is dual listed and has three core assets with multiple indications [3] Financial Position - Oculis reported $206 million in cash and cash equivalents as of March, with no debt and a runway extending into early 2028 [4] Core Assets and Indications 1. **OCS01 (OptiReach)** - A proprietary eye drop formulation of high concentration dexamethasone targeting diabetic macular edema (DME) [5][6] - Addresses a large unmet medical need with less than 60% of patients diagnosed and only 44% treated [9][10] - Estimated total US addressable patient population is 1.3 million [12] - Positive results from phase three studies, with a letter gain of 7.2 at week six and 7.6 at week twelve [13] - Safety profile is favorable with no unexpected adverse events [14] 2. **OCS05 (Preval Sector)** - A neuroprotective peptide small molecule targeting acute optic neuritis [6][18] - Demonstrated a 43% improvement in retinal ganglion cell thickness and 30% improvement in axon health at month six [25] - The indication has orphan drug designation and no approved therapies currently exist [20][33] 3. **OCS02 (Likaminomap)** - A topical anti-TNF eye drop for dry eye disease, utilizing a genotype-based precision medicine approach [34][35] - Only 13% of patients currently experience lasting relief from existing treatments [35] - Phase two study showed significant efficacy, particularly in patients with the TNF R1 genotype [38] Market Opportunity - The DME market is large and growing, with significant unmet needs due to low patient compliance with current invasive treatments [9][12] - The company aims to position OCS01 as a first-line treatment for early intervention and as a combination therapy for patients not responding adequately to existing treatments [12][17] - The total diagnosed population for DME is approximately 1.8 million, with a significant portion untreated [48] Commercial Strategy - Initial promotional efforts will focus on retinal specialists who treat patients with anti-VEGF therapies, followed by general ophthalmologists [50][51] - The company plans to leverage the existing patient base and the need for non-invasive treatment options [50][52] Future Milestones - Phase three results for OCS01 are expected in Q2 of the following year, with an NDA submission anticipated in the second half of 2026 [16][18] - Discussions with the FDA regarding registrational studies for OCS05 and OCS02 are planned for the second half of the year [33][34] Conclusion - Oculis is positioned to transform its product portfolio from ophthalmology to neuro-ophthalmology, with multiple late-stage assets and a strong clinical profile [42][43] - The company is focused on advancing its lead candidates and addressing significant unmet medical needs in the ophthalmology market [44]